Drug Profile


Alternative Names: Amatine; Gudon; Gutron; Metligine; Midodrine HCl; Midon; ProAmatine; ST 1085; TS 701

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Developer Myungmoon Pharm; Shire; Shire Pharmaceuticals Group; Taisho Pharmaceutical
  • Class Antihypotensives; Ethanolamines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Orthostatic hypotension; Urinary incontinence
  • No development reported Chronic fatigue syndrome

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 29 Mar 2012 Shire initiates two postmarketing clinical trials for Orthostatic hypotension
  • 02 Dec 2011 Shire and the US FDA Center for Drug Evaluation and Research reach an agreement to conduct two postmarketing clinical trials for Orthostatic hypotension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top